Savara Inc. (SVRA)
Savara Inc. (SVRA) is a clinical-stage pharmaceutical company focused on developing therapies for rare and ultra-rare respiratory diseases. The company's pipeline includes inhaled treatments aimed at conditions such as alveolar phospholipoproteinosis (PAP) and other rare pulmonary disorders. Savara's approach involves leveraging innovative drug delivery methods to address unmet medical needs in these specialized areas.
Company News
The Schall Law Firm is pursuing a class action lawsuit against Savara Inc. for alleged securities fraud, claiming the company made false and misleading statements about its BLA (Biologics License Application) for MOLBREEVI, which was unlikely to be approved by the FDA.
Rosen Law Firm alerts Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about the MOLBREEVI clinical trial and FDA approval process.
Read about the upcoming Wall Street events, earnings reports, conferences, and IPOs for the week ahead.
The company released first-quarter earnings and said it had completed a phase 3 trial enrollment for its lead therapy.
Savara, The LGL Group, and Harte Hanks are part of zacks Screen of the Week article.